Lisa M Ebert

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6243825/publications.pdf

Version: 2024-02-01

44 papers	2,463 citations	218381 26 h-index	243296 44 g-index
47 all docs	47 docs citations	47 times ranked	4155 citing authors

#	Article	IF	Citations
1	Desmogleinâ€2 expression is an independent predictor of poor prognosis patients with multiple myeloma. Molecular Oncology, 2022, 16, 1221-1240.	2.1	9
2	Vasculogenic mimicry structures in melanoma support the recruitment of monocytes. OncoImmunology, 2022, 11, 2043673.	2.1	8
3	Characterising Distinct Migratory Profiles of Infiltrating T-Cell Subsets in Human Glioblastoma. Frontiers in Immunology, 2022, 13, 850226.	2.2	13
4	The Role of Cytokines and Chemokines in Shaping the Immune Microenvironment of Glioblastoma: Implications for Immunotherapy. Cells, 2021, 10, 607.	1.8	32
5	3D-printed microplate inserts for long term high-resolution imaging of live brain organoids. BMC Biomedical Engineering, 2021, 3, 6.	1.7	27
6	A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma. International Journal of Molecular Sciences, 2021, 22, 4322.	1.8	26
7	Effects of Chemotherapy Agents on Circulating Leukocyte Populations: Potential Implications for the Success of CAR-T Cell Therapies. Cancers, 2021, 13, 2225.	1.7	21
8	CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix. BMC Cancer, 2021, 21, 765.	1.1	13
9	Endothelial, pericyte and tumor cell expression in glioblastoma identifies fibroblast activation protein (FAP) as an excellent target for immunotherapy. Clinical and Translational Immunology, 2020, 9, e1191.	1.7	34
10	DeepSurvNet: deep survival convolutional network for brain cancer survival rate classification based on histopathological images. Medical and Biological Engineering and Computing, 2020, 58, 1031-1045.	1.6	30
11	Platelets disrupt vasculogenic mimicry by cancer cells. Scientific Reports, 2020, 10, 5869.	1.6	18
12	Clinical chimeric antigen receptorâ€T cell therapy: a new and promising treatment modality for glioblastoma. Clinical and Translational Immunology, 2019, 8, e1050.	1.7	33
13	Glioblastoma heterogeneity and the tumour microenvironment: implications for preclinical research and development of new treatments. Biochemical Society Transactions, 2019, 47, 625-638.	1.6	104
14	Optimization of manufacturing conditions for chimeric antigen receptor T cells to favor cells with a central memory phenotype. Cytotherapy, 2019, 21, 593-602.	0.3	30
15	New approaches to model glioblastoma in vitro using brain organoids: implications for precision oncology. Translational Cancer Research, 2019, 8, S606-S611.	0.4	11
16	Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology. Biochemical Society Transactions, 2018, 46, 391-401.	1.6	26
17	A pilot study of peripheral blood BDCA-1 (CD1c) positive dendritic cells pulsed with NY-ESO-1 ISCOMATRIXâ„¢ adjuvant. Immunotherapy, 2017, 9, 249-259.	1.0	13
18	Control of immune cell entry through the tumour vasculature: a missing link in optimising melanoma immunotherapy?. Clinical and Translational Immunology, 2017, 6, e134.	1.7	32

#	Article	IF	Citations
19	A non-canonical role for desmoglein-2 in endothelial cells: implications for neoangiogenesis. Angiogenesis, 2016, 19, 463-486.	3.7	31
20	Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome. Oncotarget, 2016, 7, 46492-46508.	0.8	40
21	Interleukin-3 greatly expands non-adherent endothelial forming cells with pro-angiogenic properties. Stem Cell Research, 2015, 14, 380-395.	0.3	19
22	A selective ATP-competitive sphingosine kinase inhibitor demonstrates anti-cancer properties. Oncotarget, 2015, 6, 7065-7083.	0.8	62
23	FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis.. Oncotarget, 2014, 5, 264-276.	0.8	38
24	<scp>F</scp>lt3 ligand expands <scp>CD</scp>4⁺<scp>F</scp>ox<scp>P</scp>3⁺ regulatory <scp>T</scp> cells in human subjects. European Journal of Immunology, 2013, 43, 533-539.	1.6	47
25	Fos-icking for control of angiogenesis: increasing the longevity of peritoneal dialysis. Kidney International, 2013, 84, 1065-1067.	2.6	5
26	A novel method for detecting antigen-specific human regulatory T cells. Journal of Immunological Methods, 2012, 377, 56-61.	0.6	5
27	A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma. PLoS ONE, 2012, 7, e48424.	1.1	52
28	Evaluation of cellular immune responses in cancer vaccine recipients: lessons from NY-ESO-1. Expert Review of Vaccines, 2010, 9, 617-629.	2.0	20
29	Melan-Aâ€“specific Cytotoxic T Cells Are Associated with Tumor Regression and Autoimmunity Following Treatment with Anti-CTLA-4. Clinical Cancer Research, 2009, 15, 2507-2513.	3.2	96
30	Regulatory T-Cellâ€“Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma. Clinical Cancer Research, 2009, 15, 2166-2173.	3.2	119
31	A Long, Naturally Presented Immunodominant Epitope from NY-ESO-1 Tumor Antigen: Implications for Cancer Vaccine Design. Cancer Research, 2009, 69, 1046-1054.	0.4	48
32	Combining MHC tetramer and intracellular cytokine staining for CD8+ T cells to reveal antigenic epitopes naturally presented on tumor cells. Journal of Immunological Methods, 2009, 340, 90-94.	0.6	17
33	The Regulatory T Cellâ€“Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells. Cancer Research, 2008, 68, 3001-3009.	0.4	161
34	Directions in the immune targeting of cancer: Lessons learned from the cancerâ€testis Ag NYâ€ESOâ€1. Immunology and Cell Biology, 2006, 84, 303-317.	1.0	96
35	Comment on â€œThe Vast Majority of CLA+ T Cells Are Resident in Normal Skinâ€. Journal of Immunology, 2006, 177, 1375-1376.	0.4	5
36	Homing and Function of Human Skin Î³Î´ T Cells and NK Cells: Relevance for Tumor Surveillance. Journal of Immunology, 2006, 176, 4331-4336.	0.4	219

#	Article	IF	Citations
37	Chemokine-mediated control of T cell traffic in lymphoid and peripheral tissues. Molecular Immunology, 2005, 42, 799-809.	1.0	250
38	Cutaneous CXCL14 Targets Blood Precursors to Epidermal Niches for Langerhans Cell Differentiation. Immunity, 2005, 23, 331-342.	6.6	134
39	A Skin-selective Homing Mechanism for Human Immune Surveillance T Cells. Journal of Experimental Medicine, 2004, 199, 1265-1275.	4.2	206
40	B?cells alter the phenotype and function of follicular-homing CXCR5+ T?cells. European Journal of Immunology, 2004, 34, 3562-3571.	1.6	43
41	Lymphocyte traffic control by chemokines: follicular B helper T cells. Immunology Letters, 2003, 85, 105-112.	1.1	45
42	Up-Regulation of CCR5 and CCR6 on Distinct Subpopulations of Antigen-Activated CD4+ T Lymphocytes. Journal of Immunology, 2002, 168, 65-72.	0.4	73
43	Coregulation of CXC Chemokine Receptor and CD4 Expression on T Lymphocytes During Allogeneic Activation. Journal of Immunology, 2001, 166, 4870-4878.	0.4	39
44	Chemokines: extracellular messengers for all occasions?. BioEssays, 1999, 21, 17-28.	1.2	111